Kazia Therapeutics Limited (KZIA)Healthcare | Biotechnology | Sydney, Australia | NasdaqCM
7.42 USD
+0.01
(0.203%)
⇧
(Oct. 16, 2026, 9:41 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:02 a.m. EDT
The investment case here is structurally broken. While the company boasts a clean balance sheet with minimal debt and a recent clinical success story driving headlines, the market has priced in a catastrophic failure of the business model. The price has collapsed nearly 98% over the last nine years, with four consecutive years of negative returns ending recently. This is not a temporary setback; it is a multi-year structural decline where the market has repeatedly rejected the company's value proposition. The massive gap between the current price and the average analyst target is a red flag, not a bargain, given the persistent losses and lack of commercial revenue. For investors, this is a 'value trap' disguised as a biotech turnaround story. The short-term outlook remains murky due to the binary nature of drug development, but the long-term fundamentals are currently non-existent. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.208455 |
| AutoETS | 0.225687 |
| AutoARIMA | 0.225688 |
| MSTL | 0.231985 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 21.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.759 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.213 |
| Revenue per Share | 0.851 |
| Market Cap | 115,294,928 |
| Forward P/E | -620.96 |
| Beta | 2.27 |
| Website | https://www.kaziatherapeutics.com |
As of Oct. 10, 2026, 5:02 a.m. EDT: Speculators are positioning defensively with heavy put volume at near-the-money strikes ($7.50, $10.00) and significant open interest at deep out-of-the-money levels ($20.00), suggesting a fear of further downside or a binary event risk. Call activity is sparse and concentrated at lower strikes, indicating limited bullish conviction despite the low implied volatility environment.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.057142854 |
| Address1 | Three International Towers |
| Address2 | Level 24 300 Barangaroo Avenue |
| All Time High | 10,500.329 |
| All Time Low | 2.86 |
| Ask | 6.94 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 256,010 |
| Average Daily Volume3 Month | 274,921 |
| Average Volume | 274,921 |
| Average Volume10Days | 256,010 |
| Beta | 2.271 |
| Bid | 6.92 |
| Bid Size | 10 |
| Book Value | 2.8624136 |
| City | Sydney |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.415 |
| Current Ratio | 2.871 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.59 |
| Day Low | 7.29 |
| Debt To Equity | 0.213 |
| Display Name | Kazia Therapeutics |
| Dividend Date | 1,499,990,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,748,509,235 |
| Earnings Timestamp Start | 1,748,422,835 |
| Ebitda | -17,840,660 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.814 |
| Enterprise To Revenue | 7.65 |
| Enterprise Value | 14,525,160 |
| Eps Current Year | -0.0164 |
| Eps Forward | -0.011941272 |
| Eps Trailing Twelve Months | -6.85 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.4434 |
| Fifty Day Average Change | -4.0284004 |
| Fifty Day Average Change Percent | -0.35202828 |
| Fifty Two Week Change Percent | 5.7142854 |
| Fifty Two Week High | 17.4 |
| Fifty Two Week High Change | -9.985 |
| Fifty Two Week High Change Percent | -0.5738506 |
| Fifty Two Week Low | 4.86 |
| Fifty Two Week Low Change | 2.5549998 |
| Fifty Two Week Low Change Percent | 0.5257201 |
| Fifty Two Week Range | 4.86 - 17.4 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 915,633,000,000 |
| Float Shares | 9,391,415 |
| Forward Eps | -0.011941272 |
| Forward P E | -620.9556 |
| Free Cashflow | 1,099,920 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 6 |
| Fullday Change | 0.0149998665 |
| Fullday Change Percent | 0.2027009 |
| Fullday Price | 7.415 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,898,631 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15419 |
| Held Percent Institutions | 0.31702998 |
| Implied Shares Outstanding | 15,548,878 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,744,848,000 |
| Last Split Factor | 1:5 |
| Long Business Summary | Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. |
| Long Name | Kazia Therapeutics Limited |
| Market | us_market |
| Market Cap | 115,294,928 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_401773 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -22,800,680 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 147,092,385 |
| Number Of Analyst Opinions | 6 |
| Open | 7.44 |
| Operating Cashflow | -14,398,379 |
| Operating Margins | -146.41037 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.01 |
| Phone | 61 2 9472 4101 |
| Previous Close | 7.4 |
| Price Eps Current Year | -452.13416 |
| Price Hint | 2 |
| Price To Book | 2.590471 |
| Price To Sales Trailing12 Months | 60.725296 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.862 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0149998665 |
| Regular Market Change Percent | 0.2027009 |
| Regular Market Day High | 7.59 |
| Regular Market Day Low | 7.29 |
| Regular Market Day Range | 7.29 - 7.59 |
| Regular Market Open | 7.44 |
| Regular Market Previous Close | 7.4 |
| Regular Market Price | 7.415 |
| Regular Market Time | 1,792,158,097 |
| Regular Market Volume | 7,642 |
| Return On Assets | -0.25705 |
| Return On Equity | -1.0689601 |
| Revenue Growth | 3.124 |
| Revenue Per Share | 0.851 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,548,878 |
| Shares Percent Shares Out | 0.075500004 |
| Shares Short | 1,174,188 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 905,818 |
| Short Name | Kazia Therapeutics Limited |
| Short Percent Of Float | 0.0756 |
| Short Ratio | 3.48 |
| Source Interval | 15 |
| State | NSW |
| Symbol | KZIA |
| Target High Price | 39.062325 |
| Target Low Price | 17.421396 |
| Target Mean Price | 28.24221 |
| Target Median Price | 28.991724 |
| Total Cash | 69,459,984 |
| Total Cash Per Share | 6.127 |
| Total Debt | 98,807 |
| Total Revenue | 1,898,631 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.4546 |
| Two Hundred Day Average Change | -3.0396004 |
| Two Hundred Day Average Change Percent | -0.29074284 |
| Type Disp | Equity |
| Volume | 7,642 |
| Website | https://www.kaziatherapeutics.com |
| Zip | 2,000 |